Antengenes, ATG-022

Antengene Corporation Limited China Hong Kong

19.08.2025 - 12:40:21

Antengene's ATG-022 Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma


Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000

Logo - https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/antengenes-atg-022-cldn18-2-adc-granted-breakthrough-therapy-designation-for-the-treatment-of-gastricgastroesophageal-junction-adenocarcinoma-302533326.html

@ prnewswire.co.uk